Abstract: Techniques for actor and thread message dispatching are described herein. In some examples, a computing system may include multiple actors and multiple processing threads. Upon receiving an incoming message associated with one of the actors, a dispatching component may select one of the multiple processing threads within the computing system to which to dispatch the message for processing. If the associated actor is already assigned to one of the processing threads, then that processing thread may be selected for processing of the message. By contrast, if the associated actor is not already assigned to one of the processing threads, then a processing thread may be selected based on various factors, such as a set of priorities associated with the processing threads.

Abstract: A method and a system for rail transit communication. The method includes: selecting a second target FSO transceiver from the FSO transceivers that are currently located within a signal coverage of a target FSO base station, in response to detecting that a first target free-space-optics (FSO) transceiver moves out of the signal coverage of the target FSO base station when data communication between the target FSO base station and the target user terminal is performed via the first target FSO transceiver, where the target FSO base station is one of the FSO base stations located on the rail; and maintaining the data communication between the target FSO base station and the target user terminal, by using the second target FSO transceiver. Handover among the base stations is reduced for user equipment, data communication rate is increased, and communication experience of passengers can be improved.

Abstract: Techniques for actor and thread message dispatching are described herein. In some examples, a computing system may include multiple actors and multiple processing threads. Upon receiving an incoming message associated with one of the actors, a dispatching component may select one of the multiple processing threads within the computing system to which to dispatch the message for processing. If the associated actor is already assigned to one of the processing threads, then that processing thread may be selected for processing of the message. By contrast, if the associated actor is not already assigned to one of the processing threads, then a processing thread may be selected based on various factors, such as a set of priorities associated with the processing threads.

Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

Abstract: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.

Abstract: A method for facilitating semiconductor device manufacturing may include the following steps: receiving a custom design data set, which complies with a first element-identification scheme; generating a compatible design data set using the custom design data set, wherein data elements in the compatible design data set correspond to data elements in the custom design data set, and wherein the compatible design data set is compatible with a dummy-pattern-data generation module; generating a first dummy-pattern data set using the dummy-pattern-data generation module and the compatible design data set; and generating a second dummy-pattern data set using the first dummy-pattern data set, wherein data elements in the second dummy-pattern data set correspond to data elements in the first dummy-pattern data set, and wherein the second dummy-pattern data set complies with the first element-identification scheme.

Abstract: This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the compositions.

Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

Abstract: A layout design method is disclosed. The layout design method includes: (a) providing an original layout file; (b) performing a redundant via (RV) filling on the original layout file so as to generate a second layout file; (c) merging the second layout file with the original layout file to generate a third layout file; (d) performing a design rule check (DRC) verification on the third layout file by directly invoking a DRC code in a Process Design Kit (PDK); (e) generating, based on a result of the DRC verification, a fourth layout file including DRC errors; (f) performing a layout operation to remove DRC errors from the second layout file using the fourth layout file, so as to generate a fifth layout file; and (g) merging the fifth layout file with the original layout file to generate a sixth layout file.

Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

Abstract: A method for facilitating semiconductor device manufacturing may include the following steps: receiving a custom design data set, which complies with a first element-identification scheme; generating a compatible design data set using the custom design data set, wherein data elements in the compatible design data set correspond to data elements in the custom design data set, and wherein the compatible design data set is compatible with a dummy-pattern-data generation module; generating a first dummy-pattern data set using the dummy-pattern-data generation module and the compatible design data set; and generating a second dummy-pattern data set using the first dummy-pattern data set, wherein data elements in the second dummy-pattern data set correspond to data elements in the first dummy-pattern data set, and wherein the second dummy-pattern data set complies with the first element-identification scheme.

Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

Abstract: Compatibilized blends comprising a first phase comprising a thermoplastic olefin polymer and a second phase comprising a crosslinked, thermoplastic polyurethane are provided. The first phase is a continuous phase and the second phase can be co-5 continuous with the first phase, or dispersed as a non-continuous phase in the first phase. The blends further include a phenolic resole resin which at least partially crosslinks the thermoplastic polyurethane and acts as a compatibilizer for the olefin polymer and the thermoplastic polyurethane.

Abstract: Disclosed is a halogen-free, flame retardant thermoplastic resin composition based on polypropylene and one or more thermoplastic elastomers with an organic nitrogen- and/or phosphorus-based intumescent flame retardant comprising a piperazine component. The composition is processed easily to make a wire and cable sheath exhibiting a balance of high flame retardancy, good flexibility, high wet electrical resistance and excellent heat deformation properties, and which passes the VW-I flame retardancy test, the UL1581 heat deformation test at 150° C. and the wet electrical resistance test, and also exhibits good tensile and flexibility properties. Also disclosed is a wire and cable sheath made from the composition.

Abstract: The present invention relates to methods for treating obstructive sleep apnea (OSA), alleviating a negative OSA symptom, reducing snoring, or improving quality of life in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition comprising pyridostigmine before sleep. Also provided are related medicaments as well as methods for preparing the medicaments.

Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

Abstract: A layout design method is disclosed. The layout design method includes: (a) providing an original layout file; (b) performing a redundant via (RV) filling on the original layout file so as to generate a second layout file; (c) merging the second layout file with the original layout file to generate a third layout file; (d) performing a design rule check (DRC) verification on the third layout file by directly invoking a DRC code in a Process Design Kit (PDK); (e) generating, based on a result of the DRC verification, a fourth layout file including DRC errors; (f) performing a layout operation to remove DRC errors from the second layout file using the fourth layout file, so as to generate a fifth layout file; and (g) merging the fifth layout file with the original layout file to generate a sixth layout file.

Abstract: A method for examining quality of a dummy pattern insertion program may be implemented using a device that includes hardware. The method may include using the dummy pattern insertion program to generate a dummy-based circuit layout, a first dummy-inserted circuit layout, and a second dummy-inserted circuit layout. The method may further include determining whether the dummy-based circuit layout complies with a set of circuit layout design rules. The method may further include checking whether the first dummy-inserted circuit layout complies with at least one of a set of dummy pattern check rules and a set of pattern density rules. The method may further include examining whether the second dummy-inserted circuit layout complies with at least one of the set of circuit layout design rules, the set of dummy pattern check rules, and the set of pattern density rules.

Abstract: A composition is disclosed that includes fluorinated polymer and a non-fluorinated polymer. The fluorinated polymer includes first divalent units independently represented by formula and second divalent unit independently comprising a pendent cationic, anionic, amphoteric, or amine-oxide group or a pendent poly(alkyleneoxy) segment. The non-fluorinated polymer is R2O-(EO)p—(R3O)q-(EO)p—R2 or R2O—(R3O)q-(EO)p—(R3O)q—R2. A method of making the composition and methods of reducing the surface tension of a liquid and a method of treating a hydrocarbon-bearing formation are also disclosed.

Abstract: Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method are imino sugars and related compounds. In particular, C8-12-alkyl derivatives of N-alkyl-deoxymojirimycin, isofagomine compounds, and calystegine compounds are effective to enhance glucocerebrosidase activity.